Anaphylaxis to three humanized antibodies for severe asthma: a case study

Anaphylaxis to three humanized antibodies for severe asthma: a case study

Abstract Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case of a 35-year-old woman with severe a...

Full description

Bibliographic Details
Main Authors: Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Allergy, Asthma & Clinical Immunology
Subjects:
Anaphylaxis
Humanized antibody
Benralizumab
Omalizumab
Mepolizumab
Online Access:http://link.springer.com/article/10.1186/s13223-020-00446-w

Internet

http://link.springer.com/article/10.1186/s13223-020-00446-w

Similar Items